KalVista Pharmaceuticals develops oral small‑molecule protease inhibitors that target the kallikrein‑kinin pathway for hereditary angioedema (HAE). Its FDA‑approved drug EKTERLY (sebetralstat) provides rapid, on‑demand relief without injections, and the company’s pipeline includes an oral Factor XIIa inhibitor for prophylactic use. The products aim to improve convenience and speed of treatment for HAE patients and their prescribers.
Funding
$125M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with hereditary angioedema (HAE) rely on injectable on‑demand therapies that can be bulky, painful, and difficult to use at symptom onset, leading to delayed treatment and reduced quality of life. Existing oral options are limited, leaving a gap for rapid, convenient, and effective self‑administration during attacks.
Solution
KalVista Pharmaceuticals develops orally administered small‑molecule protease inhibitors to address the unmet need for convenient HAE treatment. Its FDA‑approved product, EKTERLY® (sebetralstat), provides rapid‑onset, on‑demand relief without injections, enabling patients to treat attacks wherever they occur. The company’s pipeline includes an oral Factor XIIa inhibitor designed for prophylactic use, expanding therapeutic options beyond acute management. All compounds target the kallikrein‑kinin pathway, delivering mechanism‑based control of swelling episodes. KalVista supports patients through a dedicated assistance program that helps navigate insurance, financial aid, and treatment logistics. Clinical development integrates feedback from the HAE community to ensure trial endpoints reflect real‑world needs.
Features
- Oral small‑molecule formulation delivering systemic exposure within minutes of ingestion
- Selective inhibition of plasma kallikrein (EKTERLY) and Factor XIIa (pipeline) to block bradykinin generation
- FDA‑approved on‑demand dosing regimen with proven rapid symptom relief in clinical trials
- Prophylactic oral Factor XIIa inhibitor candidate targeting reduction of attack frequency
- Mechanism‑based design leveraging the kallikrein‑kinin cascade for high specificity and safety
- Patient support platform (KalVista Cares) offering insurance navigation, financial assistance, and adherence resources
- Integrated clinical trial design incorporating patient‑reported outcomes and real‑world usage data